These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: concomitant assessment of perforin, IFN-gamma and IL-4 secretion. Burton CT; Gotch F; Imami N J Immunol Methods; 2006 Jan; 308(1-2):216-30. PubMed ID: 16388819 [TBL] [Abstract][Full Text] [Related]
10. ELISpot Assay for the Detection of ASFV-Specific Interferon-Gamma (IFN-γ)-Producing Cells. Portugal R Methods Mol Biol; 2022; 2503():169-178. PubMed ID: 35575894 [TBL] [Abstract][Full Text] [Related]
11. Use of interferon-γ enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus. Wang X; Greenfield WW; Coleman HN; James LE; Nakagawa M J Vis Exp; 2012 Mar; (61):. PubMed ID: 22434036 [TBL] [Abstract][Full Text] [Related]
12. Validation of a double-color ELISpot assay of IFN-γ and IL-4 production in human peripheral blood mononuclear cells. Dapporto F; De Tommaso D; Marrocco C; Piu P; Semplici C; Fantoni G; Ferrigno I; Piccini G; Monti M; Vanni F; Razzano I; Manini I; Montomoli E; Manenti A J Immunol Methods; 2024 Jan; 524():113588. PubMed ID: 38040193 [TBL] [Abstract][Full Text] [Related]
13. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. Shafer-Weaver K; Sayers T; Strobl S; Derby E; Ulderich T; Baseler M; Malyguine A J Transl Med; 2003 Dec; 1(1):14. PubMed ID: 14697097 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879 [TBL] [Abstract][Full Text] [Related]
15. Development of IFN-γ secretory ELISPOT based assay for screening of ADCC responses. Shete A; Suryawanshi P; Chavan C; Kulkarni A; Godbole S; Ghate M; Thakar M J Immunol Methods; 2017 Feb; 441():49-55. PubMed ID: 27923642 [TBL] [Abstract][Full Text] [Related]
16. ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials. Malyguine AM; Strobl S; Dunham K; Shurin MR; Sayers TJ Cells; 2012 May; 1(2):111-26. PubMed ID: 24710418 [TBL] [Abstract][Full Text] [Related]
17. Vagaries of the ELISpot assay: specific detection of antigen responsive cells requires purified CD8(+) T cells and MHC class I expressing antigen presenting cell lines. Fuchs YF; Jainta GW; Kühn D; Wilhelm C; Weigelt M; Karasinsky A; Upadhyaya B; Ziegler AG; Bonifacio E Clin Immunol; 2015 Apr; 157(2):216-25. PubMed ID: 25728493 [TBL] [Abstract][Full Text] [Related]
18. Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15--the Amplispot assay. Jennes W; Kestens L; Nixon DF; Shacklett BL J Immunol Methods; 2002 Dec; 270(1):99-108. PubMed ID: 12379342 [TBL] [Abstract][Full Text] [Related]
19. The granzyme B and interferon-gamma enzyme-linked immunospot assay as alternatives for cytotoxic T-lymphocyte precursor frequency after renal transplantation. van Besouw NM; Zuijderwijk JM; de Kuiper P; Ijzermans JN; Weimar W; van der Mast BJ Transplantation; 2005 May; 79(9):1062-6. PubMed ID: 15880044 [TBL] [Abstract][Full Text] [Related]
20. New approaches for monitoring CTL activity in clinical trials. Malyguine A; Strobl S; Zaritskaya L; Baseler M; Shafer-Weaver K Adv Exp Med Biol; 2007; 601():273-84. PubMed ID: 17713015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]